Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review

Abstract Current global variations exist in Helicobacter pylori ( H . pylori ) eradication regimens. Triple therapy (TT), bismuth quadruple therapy (BQT), and high‐dose dual therapy (HDDT) currently represent the predominant regimens. These regimens diverge in terms of treatment duration, the utilization of susceptibility testing, acid‐inhibiting drug administration, and patient education. We conducted a comprehensive systematic literature review on these H . pylori treatment regimens. Our review aims to provide standardized treatment recommendations for H . pylori , reducing the risk of amalgamating findings from diverse eradication regimens. Recent research suggests that the optimal treatment duration for TT and BQT may be 14 and 10 days, respectively. Selecting the appropriate treatment duration for HDDT should rely on regional research evidence, and 14 days may be the optimal duration. The incorporation of susceptibility testing in TT is of paramount importance. In the case of BQT, the absence of susceptibility testing may be considered as an option, contingent upon cost and availability, and should be determined based on local antibiotic resistance patterns and the efficacy of empirical regimens. The type and dosage of acid‐inhibiting drug would affect the efficacy of these regimens. Acid‐inhibiting drugs should be selected and applied reasonably according to the population and therapies. Adequate patient education plays a pivotal role in the eradication of H . pylori . In regions with accessible local research evidence, the 10‐day empirical BQT regimen may be considered a preferred choice for H . pylori eradication.